Yahoo Finance Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc
Novartis AG has the highest number of thyroid cancer drugs in development
LONDON, July 05, 2022 (GLOBE NEWSWIRE) -- The “Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report offered by GlobalData Plc provides comprehensive information on the therapeutics under development for thyroid cancer (oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. It also reviews key players involved in therapeutic development for thyroid cancer and features dormant and discontinued projects.
Leading Companies in the Thyroid Cancer Pipeline Products Market
Novartis AG: It is a healthcare company that provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others.
Advenchen Laboratories LLC: It is a pharmaceutical company that conducts research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others.
Loxo Oncology Inc: It is a biopharmaceutical company that carries out the development of targeted small molecule therapeutics for the treatment of cancer.
AstraZeneca Plc: It is a biopharmaceutical company, which develops products related to therapy areas such as respiratory, cardiovascular, renal, and metabolic diseases, cancer, autoimmune, infection, and neurological diseases.
Pfizer Inc: It offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders, and rare diseases.
Some Other Companies Covered in the Thyroid Cancer Pipeline Products Market Report
F. Hoffmann-La Roche Ltd
CSPC Pharmaceutical Group Ltd
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
AffyImmune Therapeutics Inc
Thyroid Cancer Pipeline Products Market Analysis, by Leading Companies
To know about more leading thyroid cancer pipeline product companies, download a sample report
Key Thyroid Cancer Pipeline Products Market Segment Highlights
The thyroid cancer pipeline products market report is segmented by target, MoA, RoA, and molecule type.
Thyroid Cancer Pipeline Products Market Segment Analysis by Target
Proto Oncogene Tyrosine Protein Kinase Receptor Ret
Vascular Endothelial Growth Factor Receptor 2
Serine/Threonine Protein Kinase B Raf
Programmed Cell Death Protein 1
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor Receptor 3
Others
Number of Thyroid Cancer Pipeline Products, by Target
Download a sample report for detailed target insights on the thyroid cancer pipeline products market
Thyroid Cancer Pipeline Products Market Segment Analysis by MoA
Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor
Vascular Endothelial Growth Factor Receptor 2 Inhibitor
Serine/Threonine Protein Kinase B Raf Inhibitor
Programmed Cell Death Protein 1 Antagonist
Vascular Endothelial Growth Factor Receptor 3 Inhibitor
Mast/Stem Cell Growth Factor Receptor Kit Inhibitor
Epidermal Growth Factor Receptor Inhibitor
Others
Number of Thyroid Cancer Pipeline Products, by MoA
Download a sample report for detailed MoA insights on the thyroid cancer pipeline products market
Thyroid Cancer Pipeline Products Market Segment Analysis by RoA
Oral
Intravenous
Subcutaneous
Intratumor
Intravenous Drip
Parenteral
Others
Number of Thyroid Cancer Pipeline Products, by RoA
Download a sample report for detailed RoA insights on the thyroid cancer pipeline products market
Thyroid Cancer Pipeline Products Market Segment Analysis by Molecule Type
Small Molecule
Monoclonal Antibody
Cell Therapy
Synthetic Peptide
Gene-Modified Cell Therapy
Monoclonal Antibody Conjugated
Recombinant Protein
Others
Number of Thyroid cancer Pipeline Products, by Molecule Type
Download a sample report for detailed molecule type insights on the thyroid cancer pipeline products market
Thyroid Cancer Pipeline Products Market Report Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of thyroid cancer (oncology).
The pipeline guide reviews pipeline therapeutics for thyroid cancer (oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in thyroid cancer (oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates thyroid cancer (oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews the latest news related to pipeline therapeutics for thyroid cancer (oncology)
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Find and recognize significant and varied types of therapeutics under development for thyroid cancer (oncology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding thyroid cancer (oncology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Related Reports
Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape – Click here
Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Thyroid Cancer Pipeline Products Market Overview
Targets | Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, and Others |
Mechanisms of Action | Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and Others |
Routes of Administration | Oral, Subcutaneous, Intravenous, Intratumor, Intravenous Drip, Parenteral, and Others |
Molecule Types | Small Molecule, Monoclonal Antibody, Cell Therapy, Recombinant Protein, |
Leading Companies | Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, AffyImmune Therapeutics Inc, and Others |
FAQs
What are the key targets in the thyroid cancer pipeline products market?
The key targets in the thyroid cancer pipeline products market are Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, and others.
What are the key mechanisms of action in the thyroid cancer pipeline products market?
Some of the mechanisms of action of the thyroid cancer pipeline products market are Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and others.
What are the routes of administration in the thyroid cancer pipeline products market?
The routes of administration in the thyroid cancer pipeline products market are oral, subcutaneous, intravenous, intratumor, intravenous drip, parenteral, and others.
What are the molecule types in the thyroid cancer pipeline products market?
The molecule types in the thyroid cancer pipeline products market are small molecule, monoclonal antibody, cell therapy, recombinant protein, synthetic peptide, gene-modified cell therapy, monoclonal antibody conjugated, and others.
Which are the leading companies in the thyroid cancer pipeline products market?
Some of the key companies in the thyroid cancer pipeline products market are Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, AffyImmune Therapeutics Inc, and others.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thyroid Cancer – Overview
Thyroid Cancer – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thyroid Cancer – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thyroid Cancer – Companies Involved in Therapeutics Development
Thyroid Cancer – Drug Profiles
Thyroid Cancer – Dormant Projects
Thyroid Cancer – Discontinued Products
Thyroid Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
